Immunohistochemical evaluation of cyclooxygenase expression in corneal squamous cell carcinoma in horses

American Journal of Veterinary Research

Volumn 68, Issue 2, 2007, Pages 165-170

  McInnis, Carey L ^a   Giuliano, Elizabeth A ^a   Johnson, Philip J ^a   Turk, James R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; COMPUTER; CONTROLLED STUDY; CORNEA; EYELID; HORSE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CORNEA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EYE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HORSE DISEASES; HORSES; IMMUNOHISTOCHEMISTRY; LIVER; MALE;

ANIMALIA; EQUIDAE;

EID: 33847672261     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.2.165     Document Type: Article

References (52)

1. Moore AS, Beam SL, Rassnick KM, et al. Long-term control of mucocutaneous squamous cell carcinoma and metastases in a horse using piroxicam. Equine Vet J 2003;35:715-718.
2. Dugan SJ, Curtis CR, Roberts SM, et al. Epidemiologic study of ocular/ adnexal squamous cell carcinoma in horses. J Am Vet Med Assoc 1991;198:251-256.
3. King TC, Priehs DR, Gum GG, et al. Therapeutic management of ocular squamous cell carcinoma in the horse: 43 cases (1979-1989). Equine Vet J 1991;23:449-452.
4. Dugan SJ, Roberts SM, Curtis CR, et al. Prognostic factors and survival of horses with ocular/adnexal squamous cell carcinoma: 147 cases (1978-1988). J Am Vet Med Assoc 1991;198:298-303.
5. Mosunic CB, Moore PA, Carmicheal KP, et al. Effects of treatment with and without adjuvant radiation therapy on recurrence of ocular and adnexal squamous cell carcinoma in horses: 157 cases (1985-2002). J Am Vet Med Assoc 2004;225:1733-1738.
6. McCalla TL, Moore CE, Collier LL. Immunotherapy of periocular squamous cell carcinoma with metastasis in a pony. J Am Vet Med Assoc 1992;200:1678-1681.
7. Theon AP, Pascoe JR, Madigan JE, et al. Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. Am J Vet Res 1997;58:431-436.
8. Theon AP, Pascoe JR. Iridium-192 interstitial brachytherapy for equine periocular tumours: treatment results and prognostic factors in 115 horses. Equine Vet J 1995;27:117-121.
9. Theon AP, Pascoe JR, Meagher DM. Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae. J Am Vet Med Assoc 1994;205:1170-1176.
10. Wilkie DA, Burt JK. Combined treatment of ocular squamous cell carcinoma in a horse, using radiofrequency hyperthermia and interstitial 198Au implants. J Am Vet Med Assoc 1990;196:1831-1833.
11. English RV, Nasisse MP, Davidson MG. Carbon dioxide laser ablation for treatment of limbal squamous cell carcinoma in horses. J Am Vet Med Assoc 1990;196:439-442.
12. Walker MA, Schumacher J, Schmitz DG, et al. Cobalt 60 radiotherapy for treatment of squamous cell carcinoma of the nasal cavity and paranasal sinuses in three horses. J Am Vet Med Assoc 1998;212:848-851.
13. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
14. Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol 2004;12:71-74.
15. 2 EP4 receptors. J Am Soc Nephrol 2004;15:1189-1198.
16. Robertson RP. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 1998;47:1379-1383.
17. Sorli CH, Zhang HJ, Armstrong MB, et al. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci U S A 1998;95:1788-1793.
18. Porcher C, Horowitz B, Ward SM, et al. Constitutive and functional expression of cyclooxygenase 2 in the murine proximal colon. Neurogastroenterol Motil 2004;16:785-799.
19. Jackson LM, Wu KC, Mahida YR, et al. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000;47:762-770.
20. Fang L, Chatterjee S, Dong YL, et al. Immunohistochemical localization of constitutive and inducible cyclo-oxygenases in rat uterus during the oestrous cycle and pregnancy. Histochem J 1998;30:383-391.
21. Maihofner C, Schlotzer-Schrehardt U, Guhring H, et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci 2001;42:2616-2624.
22. Damm J, Rau T, Maihofner C, et al. Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body Exp Eye Res 2001;72:611-621.
23. Hao CM, Komhoff M, Guan Y, et al. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival. Am J Physiol 1999;277:F352-F359.
24. Xiong B, Sun TJ, Hu WD, et al. Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 2005;11:1105-1108.
25. Singh B, Berry JA, Shoher A, et al. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005;26:1393-1399.
26. Tang TC, Poon RT, Lau CP, et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005;11:1896-1902.
27. Gallo O, Masini E, Bianchi B, et al. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-714.
28. Khan KN, Stanfield KM, Trajkovic D, et al. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 2001;38:116-119.
29. Khan KN, Knapp DW, Denicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
30. Kleiter M, Malarkey DE, Ruslander DE, et al. Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet Radiol Ultrasound 2004;45:255-260.
31. Laughlin MH, Turk JR, Schrage WG, et al. Influence of coronary artery diameter on eNOS protein content. Am J Physiol Heart Circ Physiol 2003;284:H1307-H1312.
32. Rush JW, Turk JR, Laughlin MH. Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium. Am J Physiol Heart Circ Physiol 2003;284:H1378-H1387.
33. Turk JR, Carroll JA, Laughlin MH, et al. C-reactive protein correlates with macrophage accumulation in coronary arteries of hypercholesterolemic pigs. J Appl Physiol 2003;95:1301-1304.
34. Kinugasa Y, Hatori M, Ito H, et al. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clip Exp Metastasis 2004;21:737-745.
35. Nozoe T, Ezaki T, Kabashima A, et al. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 2005;189:110-115.
36. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434.
37. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
38. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
39. Tjiu JW, Liao YH, Lin SJ, et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 2006;126:1143-1151.
40. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
41. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
42. Miyamoto T, Saika S, Okada Y, et al. Expression of cyclooxygenase-2 in corneal cells after photorefractive keratectomy and laser in situ keratomileusis in rabbits. J Cataract Refract Surg 2004;30:2612-2617.
43. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-614.
44. Gridelli C, Maione P, Airoma G, et al. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem 2002;9:1851-1858.
45. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274:G1061-G1067.
46. Sawaoka H, Kawano S, Tsuji S, et al. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 1998;27(suppl 1):S47-S52.
47. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996;25:333-348.
48. Narayanan BA, Narayanan NK, Pittman B, et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal antiinflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10:7727-7737.
49. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-825.
50. Lee A, Frischer J, Serur A, et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res 2006;66:4378-4384.
51. Wu YL, Fu SL, Zhang YP, et al. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 2005;59(suppl 2):S289-S292.
52. Oka T, Shearer T, Azuma M. Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res 2004;29:27-34.